25 ans de plus derrière les barreaux pour les meurtriers Jason Klaus et Joshua Frank ici.radio-canada.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ici.radio-canada.ca Daily Mail and Mail on Sunday newspapers.
Article content
A jury has acquitted a Chipman man of shooting to death two of his neighbours, convicting him of the lesser offence of manslaughter for one of the men’s deaths.
Ray Charles Nickerson, 40, learned his fate just after noon on Wednesday in an Edmonton courtroom.
We apologize, but this video has failed to load.
Try refreshing your browser, or Chipman man accused of double murder acquitted, convicted of lesser charge Back to video
The 12 jurors hearing the case convicted him of manslaughter for the death of Jason Williams, and found him not guilty in the death of Terrance Sutton. He had initially been charged with two counts of second-degree murder.
Posted: Jan 11, 2021 8:25 PM MT | Last Updated: January 12
Ray Nickerson is facing two counts of second-degree murder. (CBC)
A 40-year-old man has pleaded not guilty to two counts of second-degree murder in the deaths of two men in a small central Alberta village in 2017.
In Edmonton Court of Queen s Bench Monday, Ray Nickerson pleaded not guilty in the shooting deaths of Terry Sutton, 39, and Jason Williams, 40, in Chipman, Alta., in April 2017.
Crown prosecutor Christopher Williams said the shooting occurred the small community northeast of Edmonton after a dispute over fireworks.
Williams said on April 2, 2017, friends and family were celebrating Sutton s wife s birthday. Those in attendance were drinking, and around 11 p.m. decided to light some fireworks.
E-Mail
BOSTON - The antiepileptic drug ezogabine reduced pathologic excitability of cortical and spinal motor neuron cells that are early signs of clinical dysfunction in people with amyotrophic lateral sclerosis (ALS), according to a study conducted by the Neurological Clinical Research Institute of Massachusetts General Hospital (MGH). In addition to providing a clearer understanding of motor neuron excitability as an important disease pathway for ALS, the multi-site study, published in
JAMA Neurology, involves the first clinical investigation of ALS (also known as Lou Gehrig s disease) using a drug identified through an induced pluripotent stem cell (iPSC) model. The stem cell approach allowed us to capture the hyperexcitability of motor neurons a prominent disease phenotype and to then show ezogabine was able to reduce it in people with ALS, says lead author Brian Wainger, MD, PhD>, of the Healey Center for ALS at MGH. Our findings could have important implications f